Gut Microbiome and Alcohol-associated Liver Disease
© 2022 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved..
Changes in gut microbiota (GM) may be associated with the causation and progression of multiple liver diseases such as metabolic-associated liver disease, alcohol-associated liver disease (ALD), alcohol-associated hepatitis (AH), primary biliary cholangitis, primary sclerosing cholangitis, autoimmune liver disease, and most importantly, complications of cirrhosis and portal hypertension such as hepatic encephalopathy (HE), infection, and hepatocellular carcinoma. ALD includes simple steatosis, steatohepatitis, AH, cirrhosis, and acute-on-chronic liver failure. Alcohol consumption is associated with GM changes even before ALD development, and continued alcohol intake results in progressive dysbiosis and development of clinical events such as AH, infection, and HE. The composition and function of GM, specific changes in bacterial communities, and the functional metabolism of GM are affected in the spectrum of ALD, as revealed using high-throughput sequencing. It was reported in preliminary studies that modulation of disrupted GM improves adverse clinical events and ameliorates disease progression in ALD. In this review, we exhaustively discuss the preclinical and clinical studies on GM in ALD and critically discuss GM modulation and its effects based on various human and animal models of ALD.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Journal of clinical and experimental hepatology - 12(2022), 5 vom: 17. Sept., Seite 1349-1359 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Philips, Cyriac A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Revised 02.09.2023 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1016/j.jceh.2021.12.016 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM346733944 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM346733944 | ||
| 003 | DE-627 | ||
| 005 | 20231226032146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jceh.2021.12.016 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1155.xml |
| 035 | |a (DE-627)NLM346733944 | ||
| 035 | |a (NLM)36157139 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Philips, Cyriac A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gut Microbiome and Alcohol-associated Liver Disease |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 02.09.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2022 Indian National Association for Study of the Liver. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a Changes in gut microbiota (GM) may be associated with the causation and progression of multiple liver diseases such as metabolic-associated liver disease, alcohol-associated liver disease (ALD), alcohol-associated hepatitis (AH), primary biliary cholangitis, primary sclerosing cholangitis, autoimmune liver disease, and most importantly, complications of cirrhosis and portal hypertension such as hepatic encephalopathy (HE), infection, and hepatocellular carcinoma. ALD includes simple steatosis, steatohepatitis, AH, cirrhosis, and acute-on-chronic liver failure. Alcohol consumption is associated with GM changes even before ALD development, and continued alcohol intake results in progressive dysbiosis and development of clinical events such as AH, infection, and HE. The composition and function of GM, specific changes in bacterial communities, and the functional metabolism of GM are affected in the spectrum of ALD, as revealed using high-throughput sequencing. It was reported in preliminary studies that modulation of disrupted GM improves adverse clinical events and ameliorates disease progression in ALD. In this review, we exhaustively discuss the preclinical and clinical studies on GM in ALD and critically discuss GM modulation and its effects based on various human and animal models of ALD | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ACLF | |
| 650 | 4 | |a ACLF, acute on chronic liver failure | |
| 650 | 4 | |a AH, alcohol-associated hepatitis | |
| 650 | 4 | |a ALD | |
| 650 | 4 | |a ALD, alcohol-associated liver disease | |
| 650 | 4 | |a AUD, alcohol use disorder | |
| 650 | 4 | |a FMT | |
| 650 | 4 | |a FMT, fecal microbiota transplantation | |
| 650 | 4 | |a GM, gut microbiota | |
| 650 | 4 | |a HE, hepatic encephalopathy | |
| 650 | 4 | |a IL, interleukin | |
| 650 | 4 | |a MAFLD, metabolic-associated fatty liver disease | |
| 650 | 4 | |a SCFA, short chain fatty acids | |
| 650 | 4 | |a cirrhosis | |
| 650 | 4 | |a microbiome | |
| 700 | 1 | |a Schnabl, Bernd |e verfasserin |4 aut | |
| 700 | 1 | |a Bajaj, Jasmohan S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical and experimental hepatology |d 2011 |g 12(2022), 5 vom: 17. Sept., Seite 1349-1359 |w (DE-627)NLM214404560 |x 0973-6883 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2022 |g number:5 |g day:17 |g month:09 |g pages:1349-1359 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jceh.2021.12.016 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2022 |e 5 |b 17 |c 09 |h 1349-1359 | ||